摘要
目的探讨联合监测血浆尿激酶型纤溶酶原激活因子(urokinase type plasminogen activator,uPA)系统与血清肿瘤标记物神经原特异性烯醇化酶(neuron specific enolase,NSE)在小细胞肺癌(small cell lungcancer,SCLC)诊断、治疗和预后判断的临床价值。方法采用酶联免疫吸附法(enzyme linked immunosorbent assay,ELISA)检测48例SCLC患者和37例健康者血浆uPA及其受体(urokinase type plasminogen activator receptor,uPAR)、抑制因子-1(plasminogen activator inhibitor-1,PAI-1)的水平及血清肿瘤标记物NSE含量,并进行统计学分析。结果 SCLC患者血浆uPA、uPAR、PAI-1水平和血清NSE含量均高于正常对照组,差异有统计学意义(P<0.05)。有淋巴结转移和远处转移患者uPA、uPAR、PAI-1和NSE水平明显高于无转移患者;Ⅲ、Ⅳ期患者uPA、uPAR、PAI-1和NSE水平高于Ⅰ、Ⅱ期患者;治疗前uPA、uPAR、PAI-1及NSE水平高于治疗后;uPAR和NSE水平在各生存组间有明显差异,差异均有统计学意义(P<0.05)。血浆uPA、uPAR、PAI-1水平之间及uPAR与NSE水平之间均呈直线相关(P<0.05)。结论同血清NSE一样,血浆uPA、uPAR和PAI-1水平可作为肿瘤标记物,用于SCLC的诊断、治疗及预后判断;血浆uPAR水平和血清NSE含量的联合检测对SCLC的预后诊断有重要临床意义。
Objective To explore the clinical value of combined detection of urokinase type plasminogen activator（uPA） system in plasma and tumor markers neuron specific enolase（NSE） in serum on diagnosis,treatment and prognosis of human small cell lung cancer（SCLC）.Methods Enzyme linked immunosorbent assay（ELISA）was used to detect the levels of uPA,urokinase type plasminogen activator receptor（uPAR） and plasminogen activator inhibitor-1（PAI-1） in plasma and tumor markers NSE in serum in 48 patients with small cell lung cancer and 37 healthy subjects,and statistical analysis was performed.Results The levels of uPA,uPAR and PAI-1 in plasma,and NSE in serum,in SCLC patients were obviously higher than that in healthy subjects.（P0.05）.In SCLC,the levels of uPA,uPAR,PAI-1 and NSE of the patients with metastasis were higher than those of the patients without metastasis,the levels of uPA,uPAR,PAI-1 and NSE of the patients in TNM stages Ⅲ＋Ⅳ were higher than those in TNM stages I＋II,the levels in pre-therapy were higher than those in post-therapy,and the levels of uPAR and NSE were significantly different among groups of different survival periods（P0.05）,There were rectilinear correlation among the levels of uPA,uPAR and PAI-1,and between uPA and NSE as well（P0.05）.Conclusion Just like tumor marker NSE,the levels of uPA,uPAR and PAI-1 in plasma could be used as cancer marker on diagnosis,treatment and prognosis in SCLC.The combined detection of levels of uPAR in plasma and NSE in serum is of important clinical value to prognosis of SCLC.
出处
《中国全科医学》
CAS
CSCD
北大核心
2010年第28期3160-3162,共3页
Chinese General Practice
